NCT03745937 - A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MEDI0382

Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.

DRUG

Placebo

Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.

Trial Locations (1)

41460

Research Site, Neuss